Agios Pharmaceuticals (AGIO) Change in Receivables (2015 - 2026)
Agios Pharmaceuticals (AGIO) reported Change in Receivables of $5.6 million for Q1 2026, up 826.14% on a YoY basis from $599798.9 in Q1 2025, and little changed quarter-over-quarter from $5.5 million in Q4 2025.
Agios Pharmaceuticals (AGIO) Change in Receivables (2015 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported Change in Receivables for 9 years, with the latest figure at $5.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 826.14% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 11832.11% YoY), and the FY2025 full-year result was $6.5 million, up 397.92% from the prior year.
- Change in Receivables for Q1 2026 stood at $5.6 million, roughly flat from $5.5 million in the prior quarter.
- The five-year high for Change in Receivables was $5.6 million in Q1 2026, with the low at -$1.1 million in Q3 2023.
- Historically, Change in Receivables has averaged $948941.2 across 5 years, with a median of $473000.0 in 2023.
- Annual changes were most pronounced in 2023 — Change in Receivables plunged 588.64% — and 2026, when it jumped 826.14%.
- Agios Pharmaceuticals' Change in Receivables stood at $388000.0 in 2022, then jumped by 321.13% to $1.6 million in 2023, then slumped by 39.35% to $991000.0 in 2024, then soared by 459.84% to $5.5 million in 2025, then rose by 0.13% to $5.6 million in 2026.
- The last three Change in Receivables figures came in at $5.6 million (Q1 2026), $5.5 million (Q4 2025), and $43000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn | 5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.56 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 5.55 Mn |
| Dec 31, 2025 | 5.55 Mn |
| Sep 30, 2025 | 43,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | -765,000.00 |
| Mar 31, 2025 | -765,000.00 |
| Dec 31, 2024 | 991,000.00 |
| Dec 31, 2024 | 991,000.00 |
| Sep 30, 2024 | -644,000.00 |
| Sep 30, 2024 | -644,000.00 |
| Jun 30, 2024 | 309,000.00 |
| Jun 30, 2024 | 309,000.00 |
| Mar 31, 2024 | 643,000.00 |
| Mar 31, 2024 | 643,000.00 |
| Dec 31, 2023 | 1.63 Mn |
| Dec 31, 2023 | 1.63 Mn |